Hence, inhibition of the JAK1-STAT pathway holds promise as a therapeutic approach to prevent neoplastic progression to EATL and improve the prognosis of the disease [24]. The gene discussed is JAK1; the disease is enteropathy-associated T-cell lymphoma.